Drugs / Atipeksen
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07215416 | Aug 2026 → Dec 2032 expected | ataxia telangiectasia | Timothy Yu | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Atipeksen | “Atipeksen is a fully modified PS-2'MOE splice-switching antisense oligonucleotide” NCT07215416 ↗ |
| Action | Restore | “designed to restore normal splicing patterns” NCT07215416 ↗ |
| Modality | Antisense oligonucleotide | “mutation-specific antisense oligonucleotide (ASO)” NCT07215416 ↗ |
| Route | Intrathecal | “administered via intrathecal injection” NCT07215416 ↗ |
| Target | ATM | “Antisense oligonucleotide targeting the ATM gene” NCT07215416 ↗ |